[Radiation therapy with 131I-MIBG is still relevant for metastatic carcinoid tumors].
We report different treatment options (currently used and on trial) for a patient with a gastrointestinal carcinoid tumor and metastases in the liver, and discuss the advantages of using internal radiotherapy with 131I-MIBG rather than other treatments. According to the literature, this pathology has a poor prognosis, and considering the significant efficacy of this radiopharmaceutical treatment on symptoms, tumor reduction, and biochemical parameters, it seems to be under used. There are currently no standard treatment options. We present a management strategy for gastrointestinal carcinoid tumors with 131I-MIBG.
Oudoux
Aurore
A
Service de Médecine Nucléaire, Centre René Gauducheau, Bd Monod, Saint-Herblain.
Bridji
Boumédiène
B
Resche
Isabelle
I
Ricaud
Myriam
M
Douillard
Jean-Yves
JY
Chatal
Jean-François
JF
Rousseau
Caroline
C
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D007421:Intestine, Small / Q000473:pathology*; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D008875:Middle Aged; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine